Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

BioVaxys Acquires Full Portfolio of Former IMV

February 15, 2024

BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.

Samsung Biologics Partners with LegoChem Biosciences on ADCs

February 12, 2024

Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.

Webcasts

Avoid Clinical Manufacturing Pitfalls With These 4 Tech Transfer Best Practices

February 12, 2024

Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST

EMA Accepts Three Organizations into ATMP Pilot Program

February 09, 2024

The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.

Webcasts

A Rapid Non-destructive Approach for Moisture Determination of Lyophilized Product

February 09, 2024

Webinar Date/Time: Wed, Mar 13, 2024 11:00 AM EDT

QbD for Small-Molecule Continuous Process Development

February 03, 2024

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Compounding Overview: Primary Considerations for the Workplace

February 03, 2024

Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.

Agilent and Incyte Collaborate on Development of CDx in Hematology and Oncology

February 02, 2024

Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.

Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition

February 01, 2024

With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.

FDA Issues Guidance on CAR-T Cell Product Development

February 01, 2024

The final guidance provides specific recommendations for CMC, pharmacology, toxicology, and clinical study design for CAR-T cell products.